InVivoSIM anti-human FOLR1 (Mirvetuximab Biosimilar)

About InVivoSIM anti-human FOLR1 (Mirvetuximab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody mirvetuximab, making it ideal for research use. Mirvetuximab is a chimeric human IgG1 monoclonal antibody targeting folate receptor 1 (FOLR1), also known as folate receptor α (FRα) and folate-binding protein 1 (Fbp1). FOLR1 is a glycosylphosphatidylinositol (GPI)-anchored, high-affinity, low-throughput surface receptor for folate transport. The FOLR1-bound folate from the cell surface is brought into the cell through endocytosis. FOLR1 plays a significant role in maintaining the integrity of the genome (i.e., DNA metabolism), cell proliferation, and intracellular signaling. FOLR1’s expression is generally restricted to the luminal (apical) surface of polarized epithelia, including proximal renal tubules, lung pneumocytes, uterine appendages, epididymis, bronchial glands, placental trophoblasts, and choroid plexus (a network of blood vessels and specialized cells within the ventricles of the brain). Compared to the normal tissues, the expression of FOLR1 is more prevalent in several epithelial cancers, e.g., ovarian cancer, non-small-cell lung cancer, colon cancer, etc., making it an excellent prognostic marker as well as a target for anti-cancer therapeutics. FOLR1’s role is rapidly evolving in precision medicine, and the current FOLR1-targeted experimental therapeutics include small-molecule-drug conjugates, CAR-T cells, vaccines, and antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine. The ADC mirvetuximab soravtansine contains a mirvetuximab antibody conjugated to the cytotoxic maytansinoid DM4 via a cleavable linker, where it binds FOLR1 on tumor cells, gets internalized, and delivers DM4 to disrupt microtubule dynamics and induce apoptosis. This mirvetuximab biosimilar is an unconjugated antibody only, and it has a great binding specificity and high affinity for human FOLR1.